Gastroenterology and Hepatology

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. A Study to Evaluate the Therapeutic Effectiveness of Rifaximin in Diabetic Gastroparesis Patients Using Bloating as the Primary Endpoint

   Jacksonville, Fla.

   The primary purpose of this study is to prospectively assess symptoms of bloating (severity, prevalence) in patients with diabetic gastroparesis.

2. Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)

   Rochester, Minn., Scottsdale/Phoenix, Ariz.

   In this study, participants with MSI-H or dMMR advanced colorectal carcinoma will be randomly assigned to receive either pembrolizumab or the Investigator's choice of 1 of 6 standard of care (SOC) chemotherapy regimens for the treatment of advanced colorectal carcinoma. The primary study hypothesis is that pembrolizumab will prolong progression-free survival (PFS) or overall survival (OS) compared to current SOC chemotherapy.

3. Noninvasive Diagnosis of Patients With Bowel Diseases with Computer Aided Auscultation of Phonoenterogram

   Rochester, Minn.

   The purpose of this study is to collect and annotate PEG (Phonoenterogram) data from healthy volunteers, patients with irritable bowel syndrome (IBS), patients with inflammatory bowel disease (IBD),post-surgical patients with an increased risk of developing paralytic postoperative ileus (POI), and patients with evidence of partial bowel obstruction for facilitating the technical development of the PEG-CAAe using Artificial Intelligence.

    

4. Detection of Plasma DNA Methylation in Peripheral Blood from Patients with Hepatocellular Carcinoma

   Rochester, Minn.

   This study aims to investigate the utility of using plasma DNA methylation to detect measurable residual disease or early recurrence/progression of patients with hepatocellular carcinoma.

5. A Study to Develop a Biorepository of Blood Samples from Cancer Patients Participating in the Gemini (IRB 19-006717) Protocol

   Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to develop a biorepository of blood samples  from cancer patients participating in the Gemini (IRB 19-006717) protocol. These samples will be used for future biomarker discovery and other translational studies. 

6. Evaluating Markers which Might be a Predictor of Pancreatic Cancer or Precancer by Analyzing the Secretions (fluid) from a Pancreatic cyst

   Rochester, Minn.

   The purpose of this study is to evaluate molecular markers which might be a predictor of pancreatic cancer or precancer by analyzing the secretions (fluid) from a pancreatic cyst, pancreas fluid and tissue from a resected pancreatic cyst.

7. Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma

   Mankato, Minn., Rochester, Minn., La Crosse, Wis., Jacksonville, Fla., Eau Claire, Wis., Austin, Minn., Scottsdale/Phoenix, Ariz.

   This study will evaluate if the sponge capsule device can accurately detect the presence of Barrett's Esophagus and prevalent dysplasia/adenocarcinoma detection, in a screening population, with and without chronic gastroesophageal reflux disease.

8. A Study to Assess Clonal Diversity of Freshly Taken ESD Specimens

   Rochester, Minn.

   Inclusion Criteria:

   • Patients with Barrett’s Esophagus (BE) or Esophageal Adenocarcinoma (EAC) that are planned for Endoscopic Submucosal Dissection (ESD) treatment.

   Exclusion Criteria: 

   • Patients without BE or EAC or that are not planned for ESD treatment.

9. Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers

   Rochester, Minn.

   The purpose of this study is to compare the symptoms of patients who have a MIPG to the symptoms of patients who have a MITG.

10. Effect of Bile Acids on Satiety, Cell Function and Body Weight in Patients With Obesity and Abnormal Satiety Phenotype

    Rochester, Minn.

    The purpose of this study is to evaluate the effect of IC-CBAS 1000 mg BID on EEC function, weight loss, satiety perception, and satiety GI hormones, in patients with APS-OB phenotype. A lifestyle intervention will be provided. These consist of an obesity physician consult, a low-calorie diet instructed by registered dietitians & nutritionists, and physical activity and behavioral suggestions. These interventions should last at least the length of the study. We will include otherwise healthy patients with a BMI > 30, age range 18-65 years, and APS-OB phenotype. Based on the results of our previous trial comparing weight loss in exenatide therapy vs placebo (Acosta, Camilleri, and Burton 2015), we calculated a sample size of 18 participants per group (total of 36) with 80% power, 0.05 alpha to detect a 1 kg difference between treatment and placebo groups.